Brazil Biosimilars

Navigating Brazil’s Biosimilars Market: Intellectual Property and Regulatory Complexities

The Brazilian biosimilars market has expanded significantly, driven by complex regulatory requirements and a multifaceted intellectual property environment. Unlike generic drugs, biosimilars require comprehensive comparability studies for approval, and patent protection operates independently from marketing authorizat…